Loading…
India has seen the introduction of generic versions of GLP-1 receptor agonists for managing Type 2 Diabetes and chronic weight.
The country faces a significant public health challenge, often termed the 'diabetes capital' and grappling with a 'thin-fat' crisis.
GLP-1 drugs work by mimicking a natural hormone, helping regulate blood sugar and appetite, addressing metabolic issues.
The availability of generics aims to make these treatments more accessible in a country with a high burden of lifestyle diseases.
GLP-1 (Glucagon-like peptide-1) is a naturally occurring incretin hormone released by the intestine in response to food intake. It stimulates insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety (feeling full). GLP-1 receptor agonists are drugs that mimic this hormone's action, leading to better blood sugar control, reduced appetite, and often significant weight loss, making them effective for both Type 2 Diabetes and chronic obesity. The 'thin-fat' crisis, or TOFI (Thin Outside, Fat Inside), is a condition prevalent in South Asian populations where individuals appear lean or have a normal BMI but possess high visceral fat (fat around organs) and low muscle mass. This metabolic profile increases their risk of insulin resistance, Type 2 Diabetes, and cardiovascular diseases, even without overt obesity.
Simple Analogy: Imagine GLP-1 as a 'traffic controller' for your body's energy. It tells your pancreas to release insulin when you eat, slows down food digestion, and signals your brain that you're full. GLP-1 agonist drugs are like giving that traffic controller a megaphone, making its signals stronger and more effective for managing blood sugar and weight.
Diabetes and obesity are major NCDs, a significant public health challenge globally and in India, requiring comprehensive prevention and management strategies.
The NHM focuses on strengthening healthcare systems and addressing NCDs through various programs, aligning with efforts to combat diabetes and obesity.
Aims to provide universal health coverage, which includes managing chronic diseases like diabetes and obesity through accessible healthcare services.
The development and availability of generic drugs, regulated by bodies like the DCGI, play a key role in making essential medicines affordable and accessible to a wider population.
GS-III Science & Technology (Developments in Biotechnology, Health); GS-II Social Justice (Health, Human Development). Questions can be conceptual, statement-based on drug mechanisms, public health policies, or the 'thin-fat' phenomenon.
General Science (Biology, Human Diseases); General Awareness (Health & Welfare). Expect factual questions on GLP-1, diabetes, or related terms.
General Awareness (Science & Technology, Current Affairs related to Health). Questions on medical terms, diseases, or new drug developments.
General Science (Biology, Health); General Awareness. Similar to SSC, focusing on basic scientific facts and health issues.
General Science. Basic understanding of human biology and diseases.
Consider the following statements : 1. The India Sanitation Coalition is a platform to promote sustainable sanitation and is funded by the Government of India and the World Health Organization. 2. The National Institute of Urban Affairs is an apex body of the Ministry of Housing and Urban Affairs in Government of India and provides innovative solutions to address the challenges of Urban India. Which of the statements given above is/are correct?
Answer: 2 only
Consider the following pairs: 1. Radhakanta Deb - First President of the British Indian Association 2. Gazulu Lakshminarasu Chetty - Founder of the Madras Mahajana Sabha 3. Surendranath Banerjee - Founder of the Indian Association Which of the above pairs is/are correctly matched?
Answer: 1 and 3 only
The Radcliffe Committee was appointed to
Answer: delimit the boundaries between India and Pakistan
High, especially for Science & Technology and Social Issues sections, given the public health implications and scientific advancements.
A class of drugs that mimic the natural hormone GLP-1 to regulate blood sugar and appetite.
A condition of normal BMI but high body fat and low muscle mass, leading to metabolic risks.
Chronic diseases that are not passed from person to person, such as heart disease, cancer, diabetes, and chronic respiratory diseases.
A cluster of conditions that occur together, increasing your risk of heart disease, stroke and type 2 diabetes.